Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle

A technology of Mycoplasma hyopneumoniae and Mycoplasma bovis is applied in the field of treating or preventing diseases or diseases caused by Mycoplasma bovis infection in animals, and can solve problems such as unrecognized protective effects and the like

Inactive Publication Date: 2005-05-04
PFIZER PRODS ETAT DE CONNECTICUT
View PDF8 Cites 15 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] Prior to the present invention, it had not been recognized that a M. hyopneumoniae vaccine would protect cattle against disease caused by M. bovis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle
  • Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0074] Materials and Methods

[0075] animal

[0076] Healthy crossbred dairy calves are vaccinated at approximately 14 days of age. The calves were acclimated for 7 days before starting the study. All calves received a daily concentrated unmedicated diet without any known contaminants or pesticides, but had free access to water.

[0077] vaccine

[0078] The bacterin used to immunize calves contains an appropriate concentration of BEI-inactivated whole cells of Mycoplasma hyopneumoniae per dose. Additionally, the vaccine preparation comprises phosphate buffered saline (PBS) and an oil-in-water adjuvant. Placebo contained PBS.

[0079] attack method

[0080] Each calf received 12 ml of fresh M. bovis culture (approximately 1 × 10 8 to 1×10 10 Colony forming units (CFU / ml)). Immediately after completion of each experimental challenge, the viable number (CFU / ml) of the challenge inoculum was determined.

[0081] Experimental procedure

[0082] Each calf is identifie...

Embodiment 2

[0092] In this example, the efficacy of the M. hyopneumoniae bacterin was assessed in young calves. Thirty healthy hybrid calves were randomly grouped according to age.

[0093] On day 0 (left neck) and day 21 (right neck), animals were inoculated subcutaneously with 2 ml of the vaccine or placebo. The experimental treatment groups and vaccines used are shown in Table 1.

[0094] therapy group

[0095] Calves were challenged as described above 3 weeks after the second inoculation. Each calf received 12 ml of fresh M. bovis culture for 3 consecutive days by the intranasal route.

[0096] Within 1 hour after completion of the M. bovis experimental challenge, the number of surviving inoculum per challenge (CFU / ml) was determined. The results are shown in Table 2.

[0097] Table 2

[0098] challenge culture

[0099] Rectal temperatures were measured every morning on the day before the experimental M. bovis challenge, immediately before the st...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to View More

Abstract

The present invention relates to methods for treating or preventing a disease or disorder in an animal caused by infection by Mycoplasma bovis (M. bovis) by administering to the animal an effective amount of a Mycoplasma hyopneumoniae (M. hyo) vaccine. The M. hyo vaccine can be a whole or partial cell inactivated or modified live preparation, a subunit vaccine, or a nucleic acid or DNA vaccine. The M. hyo vaccine administered in accordance with the present invention can be synthesized or recombinantly produced.

Description

technical field [0001] The invention relates to a method for treating or preventing diseases or diseases caused by Mycoplasma bovis (M.bovis) infection in animals by administering effective doses of Mycoplasma hyopneumoniae (M.hyo) vaccine to animals. The Mycoplasma hyopneumoniae vaccine may be an inactivated whole cell or a part of the cell, or a modified live product, a subunit vaccine, or a nucleic acid or DNA vaccine. The M. hyopneumoniae vaccine administered in accordance with the present invention may be synthetically or recombinantly prepared. Background technique [0002] M. bovis is a bovine pathogen in captive or intensively reared cattle or dairy cattle. The most reported clinical manifestation is pneumonia in calves, which is often accompanied by arthritis, also known as pneumonia-arthritis syndrome. Its etiological role has also been implicated in mastitis, otitis, and reproductive diseases or conditions in cows and bulls. M. bovis-induced respiratory disease...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/00A61K39/02A61K39/04A61K39/39A61P31/00
CPCY10S435/87A61K2039/521A61K39/0241A61K2039/552A61K2039/55566A61P31/00A61P31/04
Inventor 亚历山大·C·古迪安德鲁·R·彼得斯罗宾·L·凯奇
Owner PFIZER PRODS ETAT DE CONNECTICUT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com